GlycoMimetics, Inc. (GLYC)

Oncology Corporate Profile

Stock Performance

12.1000
0.6000

HQ Location

401 Professional Drive #25
Gaithersburg, MD 20879

Company Description

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology (glycobiology) plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.

Website: http://www.glycomimetics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
GMI-1271E-selectin antagonistAcute Myelogenous Leukemia (AML)IIGlycoMimetics
GMI-1271E-selectin antagonistMultiple MyelomaIGlycoMimetics
GMI-1359CXCR4 antagonistVarious cancer typesIGlycoMimetics

View additional information on product candidates here »

Source: http://www.glycomimetics.com

Recent News Headlines

7/25/2017 12:23 am

7/25/2017 12:23 am

7/25/2017 12:23 am

7/25/2017 12:23 am

7/25/2017 12:23 am

7/19/2017 06:18 am

7/19/2017 06:18 am

7/19/2017 06:18 am

7/19/2017 06:18 am

7/19/2017 06:18 am

7/6/2017 06:18 am

7/6/2017 06:18 am

7/6/2017 06:18 am

7/6/2017 06:18 am

7/6/2017 06:18 am

6/30/2017 06:18 am

6/30/2017 06:18 am

6/30/2017 06:18 am

6/30/2017 06:18 am

6/30/2017 06:18 am

6/12/2017 06:18 am

6/7/2017 06:18 am

6/5/2017 12:18 pm

6/5/2017 06:18 am

6/5/2017 12:18 am